Loreev Xr is owned by Almatica.
Loreev Xr contains Lorazepam.
Loreev Xr has a total of 1 drug patent out of which 0 drug patents have expired.
Loreev Xr was authorised for market use on 27 August, 2021.
Loreev Xr is available in capsule, extended release;oral dosage forms.
Loreev Xr can be used as once daily treatment of anxiety disorder in adults.
The generics of Loreev Xr are possible to be released after 08 January, 2034.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8999393||ALMATICA||Sustained release formulations of lorazepam|| |
(10 years from now)
Drugs and Companies using LORAZEPAM ingredient
Market Authorisation Date: 27 August, 2021
Treatment: Once daily treatment of anxiety disorder in adults
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic